Han-I Wang1, Eline Aas2, Debra Howell3, Eve Roman3, Russell Patmore4, Andrew Jack5, Alexandra Smith3. 1. Epidemiology & Cancer Statistics Group, University of York, York, UK. Electronic address: Han-I.Wang@ecsg.york.ac.uk. 2. Department of Health Management and Health Economics, University of Oslo, Oslo, Norway. 3. Epidemiology & Cancer Statistics Group, University of York, York, UK. 4. Queens Centre for Oncology and Haematology, Castle Hill Hospital, Hull, UK. 5. Haematological Malignancy Diagnostic Service, St James's University Hospital, Leeds, UK.
Abstract
BACKGROUND: Acute myeloid leukemia (AML) can be diagnosed at any age and treatment, which can be given with supportive and/or curative intent, is considered expensive compared with that for other cancers. Despite this, no long-term predictive models have been developed for AML, mainly because of the complexities associated with this disease. OBJECTIVE: The objective of the current study was to develop a model (based on a UK cohort) to predict cost and life expectancy at a population level. METHODS: The model developed in this study combined a decision tree with several Markov models to reflect the complexity of the prognostic factors and treatments of AML. The model was simulated with a cycle length of 1 month for a time period of 5 years and further simulated until age 100 years or death. Results were compared for two age groups and five different initial treatment intents and responses. Transition probabilities, life expectancies, and costs were derived from a UK population-based specialist registry-the Haematological Malignancy Research Network (www.hmrn.org). RESULTS: Overall, expected 5-year medical costs and life expectancy ranged from £8,170 to £81,636 and 3.03 to 34.74 months, respectively. The economic and health outcomes varied with initial treatment intent, age at diagnosis, trial participation, and study time horizon. The model was validated by using face, internal, and external validation methods. The results show that the model captured more than 90% of the empirical costs, and it demonstrated good fit with the empirical overall survival. CONCLUSIONS: Costs and life expectancy of AML varied with patient characteristics and initial treatment intent. The robust AML model developed in this study could be used to evaluate new diagnostic tools/treatments, as well as enable policy makers to make informed decisions.
BACKGROUND:Acute myeloid leukemia (AML) can be diagnosed at any age and treatment, which can be given with supportive and/or curative intent, is considered expensive compared with that for other cancers. Despite this, no long-term predictive models have been developed for AML, mainly because of the complexities associated with this disease. OBJECTIVE: The objective of the current study was to develop a model (based on a UK cohort) to predict cost and life expectancy at a population level. METHODS: The model developed in this study combined a decision tree with several Markov models to reflect the complexity of the prognostic factors and treatments of AML. The model was simulated with a cycle length of 1 month for a time period of 5 years and further simulated until age 100 years or death. Results were compared for two age groups and five different initial treatment intents and responses. Transition probabilities, life expectancies, and costs were derived from a UK population-based specialist registry-the Haematological Malignancy Research Network (www.hmrn.org). RESULTS: Overall, expected 5-year medical costs and life expectancy ranged from £8,170 to £81,636 and 3.03 to 34.74 months, respectively. The economic and health outcomes varied with initial treatment intent, age at diagnosis, trial participation, and study time horizon. The model was validated by using face, internal, and external validation methods. The results show that the model captured more than 90% of the empirical costs, and it demonstrated good fit with the empirical overall survival. CONCLUSIONS: Costs and life expectancy of AML varied with patient characteristics and initial treatment intent. The robust AML model developed in this study could be used to evaluate new diagnostic tools/treatments, as well as enable policy makers to make informed decisions.
Authors: Michael R McKeown; Liv Johannessen; Emily Lee; Christopher Fiore; Emmanuelle di Tomaso Journal: Haematologica Date: 2018-10-18 Impact factor: 9.941
Authors: Lisa Pleyer; Sonja Burgstaller; Reinhard Stauder; Michael Girschikofsky; Heinz Sill; Konstantin Schlick; Josef Thaler; Britta Halter; Sigrid Machherndl-Spandl; Armin Zebisch; Angelika Pichler; Michael Pfeilstöcker; Eva-Maria Autzinger; Alois Lang; Klaus Geissler; Daniela Voskova; Dietmar Geissler; Wolfgang R Sperr; Sabine Hojas; Inga M Rogulj; Johannes Andel; Richard Greil Journal: J Hematol Oncol Date: 2016-04-16 Impact factor: 17.388
Authors: Erin L Tomaszewski; Catherine E Fickley; LeAnne Maddux; Robert Krupnick; Erkut Bahceci; Jean Paty; Floortje van Nooten Journal: Oncol Ther Date: 2016-09-02
Authors: Maria Mareque; Pau Montesinos; Patricia Font; José María Guinea; Adolfo de la Fuente; Javier Soto; Itziar Oyagüez; James Brockbank; Tamara Iglesias; Julia Llinares; Jorge Sierra Journal: Clinicoecon Outcomes Res Date: 2021-04-22
Authors: Sonya Cressman; Aly Karsan; Donna E Hogge; Emily McPherson; Corneliu Bolbocean; Dean A Regier; Stuart J Peacock Journal: Br J Haematol Date: 2016-04-21 Impact factor: 6.998
Authors: Alexandra Smith; Debra Howell; Simon Crouch; Dan Painter; John Blase; Han-I Wang; Ann Hewison; Timothy Bagguley; Simon Appleton; Sally Kinsey; Cathy Burton; Russell Patmore; Eve Roman Journal: Int J Epidemiol Date: 2018-06-01 Impact factor: 7.196